869725-57-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-Inden-1-ol, 2,3-dihydro-5-(trifluoromethyl)is used as a building block for the synthesis of pharmaceuticals, leveraging its chemical properties to create a variety of medicinal compounds.
Used in Organic Synthesis:
1H-Inden-1-ol, 2,3-dihydro-5-(trifluoromethyl)is used as a starting material for the production of other fluorinated compounds, contributing to the development of new organic compounds with potential applications in various fields.
Used as a Solvent:
In the chemical industry, 1H-Inden-1-ol, 2,3-dihydro-5-(trifluoromethyl)is utilized as a solvent in various chemical reactions, facilitating the process due to its compatibility with a range of substances.
Used in Chemical Transformations:
Due to its reactivity, 1H-Inden-1-ol, 2,3-dihydro-5-(trifluoromethyl)is employed in various chemical transformations, allowing for the creation of diverse organic molecules with specific properties and applications.

InChI:InChI=1/C10H9F3O/c11-10(12,13)7-2-3-8-6(5-7)1-4-9(8)14/h2-3,5,9,14H,1,4H2

Upstream product

• 511533-38-3 5-iodoindan-1-one 
• 3470-54-0 5-aminoindan-1-one 
• 102684-91-3 2-bromo-5-(trifluoromethyl)benzaldehyde 
• 1483-55-2 2-bromo-5-trifluoromethylbenzonitrile 
• 869725-56-4 3-[2-bromo-5-(trifluoromethyl)phenyl]propanoic acid 
• 869725-54-2 1-bromo-2-(chloromethyl)-4-(trifluoromethyl)benzene 
• 869725-53-1 (2-bromo-5-(trifluoromethyl)phenyl)methanol 
• 150969-56-5 5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 1279722-81-4 Br^(1-)*C₂₈H₂₃F₃P⁽¹⁺⁾ 

Relevant academic research and scientific papers

ATF6 MODULATORS AND USES THEREOF

Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Rhodium-catalyzed synthesis of 2,3-disubstituted indoles from β,β-Disubstituted stryryl azides

Rings la carte: Rhodium carboxylate complexes catalyze selective cascade reactions to produce a range 2,3-disubstituted indoles from β,β- disubstituted stryryl azides. The selective migration of aryl groups appears to originate from a putative phenonium ion reactive intermediate (see scheme).

Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity

To identify a CCR5 antagonist as an HIV-1 entry inhibitor, we designed a novel series of indane derivatives based on conformational considerations. Modification on the indane ring led to the discovery of compound 22a (INCB9471) that exhibited high affinit

Piperazinylpiperidine derivatives as chemokine receptor antagonists

The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR